Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy

• DOI: 10.1016/j.ajog.2022.04.009
• Publication Date: 2022-04-14T14:48:31Z
• Authors: Yannic C. Bartsch; Caroline Atyeo; Jaewon Kang; Yongfei Cai; Bing Chen; Kathryn J. Gray; Andrea G. Edlow; Galit Alter
• Keywords: 0301 basic medicine; Vaccines; COVID-19 Vaccines; Membrane Glycoproteins; SARS-CoV-2; Vaccination; COVID-19; Receptors, Fc; Antibodies, Viral; 3. Good health; 03 medical and health sciences; Viral Envelope Proteins; Pregnancy; Spike Glycoprotein, Coronavirus; Humans; Female; RNA, Messenger; Pregnancy Complications, Infectious; Original Research

SARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among pregnant women. Just as coordinated messaging from the Centers for Disease Control and Prevention and leading obstetrics organizations began to increase vaccine confidence in this vulnerable group, the evolution of SARS-CoV-2 variants of concerns, including the Omicron variant, raised new concerns about vaccine efficacy because of their ability to escape vaccine-induced neutralizing antibodies. Early data point to a milder disease course following infection with the Omicron variant in vaccinated individuals. Thus, these data suggest that alternate vaccine-induced immunity beyond neutralization may continue to attenuate Omicron variant-induced disease, such as Fc-mediated antibody activity.This study aimed to test whether vaccine-induced antibodies raised during pregnancy continue to bind to and leverage Fc receptors to protect against variants of concern including the Omicron variant.The receptor binding domain or whole spike-specific antibody isotype binding titers and Fc gamma receptor binding directed toward variants of concern, including the Omicron variant, were analyzed in pregnant women after receiving the full dose regimen of either the Pfizer/BioNTech BNT62b2 (n=10) or Moderna mRNA-1273 (n=10) vaccination using a multiplexing Luminex assay.Reduced isotype recognition of the Omicron receptor binding domain was observed following administration of either vaccine with relatively preserved, albeit reduced, recognition of the whole Omicron spike by immunoglobulin M and G antibodies. Despite the near complete loss of Fc receptor binding to the Omicron receptor binding domain, Fc receptor binding to the Omicron spike was more variable but largely preserved.Reduced binding titers to the Omicron receptor binding domain aligns with the observed loss of neutralizing activity. Despite the loss of neutralization, preserved, albeit reduced, Omicron spike recognition and Fc receptor binding potentially continue to attenuate disease severity in pregnant women.